Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study.

ABSTRACT:

Objectives

Ceftriaxone is widely used for hospitalized patients with community-acquired pneumonia, but its optimal dosage remains unclear.

Methods

We retrospectively identified patients diagnosed with pneumonia between July 2010 and March 2022 from the Diagnosis Procedure Combination inpatient database in Japan. They were categorized into those receiving 2 or 1 g/day of ceftriaxone within the first 2 days of hospitalization. The primary outcome was 30-day in-hospital mortality. The secondary outcomes included overall adverse events (composite of biliary tract infection, Clostridioides difficile infection and allergic reactions) and each adverse event. A subgroup analysis was conducted for patients requiring mechanical ventilation. Propensity-score overlap-weighting analysis

SUBMITTER: Taniguchi J 

PROVIDER: S-EPMC12313466 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature